Skip to main content
    A

    Arcutis Biotherapeutics Inc (ARQT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $27.33
    +0.18 (+0.66%)

    Market Cap: $3.43B

    Last updated: Nov 17, 2026 at 4:33 PM ET

    Arcutis Biotherapeutics Inc (ARQT) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Arcutis Biotherapeutics (ARQT) has a market cap of $3.43B and an enterprise value of $3.51B. Revenue grew 60.00% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 2.21% above the market cap, as debt exceeds cash.

    Market Cap$3.43B
    Enterprise Value$3.51B
    Latest price (Nov 17, 2026)$27.33

    Key Dates

    The next earnings report is expected on Feb 23, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 23, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.37% in the quarter ended Sep 30, 2026 and grew 2.66% a year over 2 years.

    Shares Outstanding131.01M
    Shares Change (YoY)+2.65%
    Shares Change (QoQ)+0.37%
    Share Count Growth (2Y CAGR)+2.66%

    Valuation Ratios

    Sales and book value multiples are 7.0x and 14.7x.

    P/E Ratio130.1x
    Forward P/E88.2x
    P/S Ratio7.0x
    Forward P/S6.3x
    P/B Ratio14.7x
    P/TBV Ratio15.5x
    P/OCF Ratio57.3x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 115.6x EBITDA.

    EV / Earnings117.3x
    EV / Sales6.9x
    EV / EBITDA115.6x

    Price Statistics

    The stock is up 9.32% over 52 weeks and trades 1.19% below its 50-day average.

    Beta (1Y)1.57
    52-Week Change+9.32%
    1-Month Change-14.30%
    3-Month Change+3.29%
    6-Month Change+40.15%
    5-Year Change+51.42%
    Total Return (1Y)+9.32%
    Total Return (3Y CAGR)+137.46%
    Total Return (5Y CAGR)+7.73%
    Return vs SPY (1Y)-11.38%
    Max Drawdown (1Y)-37.50%
    Max Drawdown (3Y)-42.22%
    Sharpe Ratio (1Y)0.00
    Correlation with SPY (1Y)0.38
    50-Day Average$27.66
    200-Day Average$25.40
    52-Week Range$19.30 to $34.80
    RSI (14 Days)45.6
    Average Volume (20 Days)2.24M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.92x current liabilities, and total debt is 0.45x shareholder equity.

    Current Ratio2.92x
    Quick Ratio2.66x
    Debt / Equity0.45x
    Debt / EBITDA3.46x
    Debt / FCF1.83x
    Interest Coverage2.07x

    Returns and Efficiency

    Return on invested capital is 7.83% over the last 12 months, against a 5-year average of -26.21%.

    Return on Equity (ROE)12.26%
    Return on Assets (ROA)5.70%
    Return on Invested Capital (ROIC)7.83%
    ROA (5Y Average)-48.11%
    ROIC (5Y Average)-26.21%
    Asset Turnover1.14x
    Inventory Turnover1.06x
    Receivables Turnover3.12x
    Cash Conversion Cycle400 days

    Taxes

    Income tax took 2.90% of pretax income over the last 12 months.

    Income Tax (TTM)$894.00K
    Effective Tax Rate2.90%

    Scores

    ARQT has an Altman Z-Score of 6.56, in the safe zone above 2.99, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.

    Altman Z-Score6.56
    Altman Z ZoneSafe
    Piotroski F-Score4 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $508.68M over the last 12 months.

    Revenue$508.68M
    Revenue Growth (YoY)+60.00%
    Gross Profit$463.81M
    Operating Income$35.16M
    Pretax Income$30.80M
    Net Income$29.91M
    Reported EPS (TTM)$0.21

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 46.52% of the $524.43M in total assets.

    Cash and Equivalents$33.37M
    Total Debt$109.40M
    Net Debt$76.03M
    Net Debt Per Share$0.58
    Working Capital$331.33M
    Shareholder Equity$243.97M
    Book Value Per Share$1.86
    Tangible Book Value$230.84M
    Tangible Book Per Share$1.76
    Total Assets$524.43M
    Total Liabilities$280.46M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $255.00K of capital spending, operating cash flow left $59.71M of free cash flow.

    Operating Cash Flow$59.96M
    Capital Expenditures$255.00K
    Free Cash Flow$59.71M
    FCF Per Share$0.48
    Depreciation and Amortization$3.13M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 6.91%.

    Gross Margin91.18%
    Operating Margin6.91%
    Pretax Margin6.06%
    Net Margin5.88%
    FCF Margin11.74%

    Growth

    Revenue grew 367.27% a year over 3 years.

    Revenue Growth (3Y CAGR)+367.27%
    Book Value Per Share Growth (2Y CAGR)+20.77%
    Tangible Book Per Share Growth (2Y CAGR)+20.41%

    Revenue and profit by year

    Dividends and Yields

    ARQT does not pay a dividend.

    Earnings Yield0.77%
    Buyback Yield-0.03%
    Shareholder Yield-0.03%

    Peer Position

    Against 9 similar companies, ARQT has the 8th highest P/S and the highest ROIC.

    P/S Ratio7.0x vs 13.1x median
    ROIC7.83% vs -41.75% median
    Revenue Growth (Trailing 4 Quarters, YoY)+60.00% vs +25.30% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 36.72% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+36.72%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ARQT

    What is ARQT's market cap?

    Arcutis Biotherapeutics has a market cap of $3.43B. Its enterprise value, which adds debt and subtracts cash, is $3.51B.

    What is ARQT's P/E ratio?

    Arcutis Biotherapeutics has a trailing P/E ratio of 130.1x and a forward P/E of 88.2x.

    How many shares of ARQT are outstanding?

    Arcutis Biotherapeutics has 131.01M shares outstanding. The count is up 2.65% from a year earlier.

    Does ARQT pay a dividend?

    No. Arcutis Biotherapeutics does not pay a dividend.

    How much debt does ARQT have?

    Arcutis Biotherapeutics has $109.40M of total debt and $33.37M of cash and equivalents, a net debt position of $76.03M.